Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Yan, Tristan D ^a   Stuart, Oswald A ^a   Yoo, Dal ^a   Sugarbaker, Paul H ^a  

^a WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; OXALIPLATIN; PACLITAXEL;

ABDOMINAL DISTENSION; APPENDIX CANCER; ASCITES; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM CANCER; DISSEMINATED CANCER; DRUG MECHANISM; DRUG PENETRATION; DRUG TISSUE LEVEL; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTESTINE OBSTRUCTION; NEPHROTOXICITY; OVARY CANCER; PERIOPERATIVE PERIOD; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PERITONEUM METASTASIS; PERITONEUM PSEUDOMYXOMA; PROGNOSIS; QUALITY OF LIFE; REVIEW;

EID: 33745646072     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-17     Document Type: Review

References (54)

1. Fujimura T, Yonemura Y, Fujita H, Michiwa Y, Kawamura T, Nojima N, Sato T, Fushida S, Nishimura G, Miwa K, Miyazaki I, Murakami K, Katayama K, Yamaguchi A: Chemohyperthermic peritoneal perfusion for peritoneal dissemination in various intra-abdominal malignancies. Int Surg 1999, 84:60-66.
2. Pestieau SR, Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. Dis Colon Rectum 2000, 43:1341-1346.
3. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH: Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 2000, 87:1587-1593.
4. Sugarbaker PH: Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001, 27:239-243.
5. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001, 92:71-76.
6. Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijen JH, van Slooten GW, van Coevorden F, Zoetmulder FA: Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001, 37:979-984.
7. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA: Prospective trial for the treatment of malignant peritoneal mesothelioma. American Surgeon 2001, 67:999-1003.
8. Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA: Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surgery 2001, 88:458-463.
9. Piso P, Bektas H, Werner U, Schlitt HJ, Kubicka S, Bornscheuer A, Manns M, Klempnauer J: Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma. Eur J Surg Oncol 2001, 27:286-290.
10. Butterworth SA, Panton ON, Klaassen DJ, Shah AM, McGregor GI: Morbidity and mortality associated with intraperitoneal chemotherapy for Pseudomyxoma peritonei. Am J Surg 2002, 183:529-532.
11. Sugarbaker PH, Welch LS, Mohamed F, Glehen O: A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 2003, 12:605-621.
12. Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003, 21(24):4560-4567.
13. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003, 21:3737-3743.
14. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004, 14:35-41.
15. Glehen 0, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer. A multi-institutional study of 506 patients. J Clin Oncol 22(16):3284-3292. 2004 Aug 15
16. Torres IL, Litterst CL, Guarino AM: Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 1978, 17:330-340.
17. Hahn GM: Potential for therapy of drugs and hyperthermia. Cancer Res 1979, 39:2264-2268.
18. Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH: Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003, 10(4):463-468.
19. Jacquet P, Averbach A, Stuart OA, Chang D, Sugarbaker PH: Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism and tissue distribution in a rat model. Cancer Chemother Pharmacol 1998, 41:147-154.
20. Los G, Smals OAG, van Vugt MJH: A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 1992, 52:1252-1258.
21. Sugarbaker, Graves T, DeBruijn EA, Cunliffe WJ, Mullins RE, Hull WE, Oliff L, Schlag P: Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 1990, 50:5790-5794.
22. Sugarbaker PH, Yan TD, Stuart OA, Yoo D: Progress in management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol in press.
23. Jacquet P, Stuart OA, Chang D, Sugarbaker PH: Effects of intraabdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 1996, 7:596-603.
24. Sugarbaker PH: Early postoperative intraperitoneal Adriamycin as an adjunctive treatment for advanced gastric cancer with lymph node or serosal invasion. Edited by: Sugarbaker PH. Management of Gastric Cancer. Kluwer: Boston; 1991:277-284.
25. Sugarbaker PH: Early postoperative intraperitoneal Adriamycin as an adjunctive treatment for visceral and retroperitoneal sarcoma. Edited by: Sugarbaker PH. Management of Gastric Cancer Kluwer Boston; 1996:7-14.
26. Yan TD, Stuart OA, Sugarbaker PH: Pharmacokinetic profile of heated intraoperative intraperitoneal doxorubicin for diffuse malignant peritoneal mesothelioma. (Submitted for publication)
27. Los G, van Yugt MJH, den Engelse, Pinedo HM: Effects of the temperature on the interaction of cisplatin and carboplatin with cellular DNA. Biochem Pharmacol 1993, 46:1229-1237.
28. Kuh HJ, Jang SH, Wientjes MG, Weaver JR, Au JL: Determinants of paclitaxel penetration and accumulation in human solid tumor. J Pharmacal Exp Ther 1999, 290:871-880.
29. Mohamed F, Marchettini P, Stuart OA, Yoo D, Sugarbaker PH: A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery. Eur J Surg Oncol 2003, 29:261-265.
30. Yan TD, Yoo D, Sugarbaker PH: Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. (Submitted to publication)
31. Sugarbaker PH: The natural history, gross pathology and histopathology of appendiceal epithelial neoplasms. Eur J Surg Oncol in press.
32. van Ruth S, Verwaal VJ, Zoetmulder FAN: Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am 2003, 12:771-780.
33. Sugarbaker PH, Stuart OA, Carmignani CP: Pharmacokinetic changes induced by the volume of chemotherapy solutions in patients treated with hyperthermic intraperitoneal mitomycin C. Cancer Chemother Pharmacol 11:1-6. 2005 Aug
34. Sugarbaker PH, Chang D: Epithelial appendiceal neoplasm with peritoneal dissemination. Update on a comprehensive management strategy in 803 patients with pseudomyxoma peritonei. (Submitted for publication)
35. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC: Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 1989, 63:364-367.
36. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Francois Y, Vignal J, Gilly FN: Peritoneal carcinomatosis from nongynecologic malignancies: results of the EVOCAPE I multi-centeric prospective study. Cancer 2000, 88:58-63.
37. Le vi F, Zidani R, Brienza S, Dogliotti L, Perpoint B, Rotarski M, Letourneau Y, Llory JF, Chollet P, Le Rol A, Focan C: A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-flurouracil and leucovorin as initial treatment of patients with metastatic colorectal carcinoma: International Organization for Cancer Chronotherapy. Cancer 1999, 85:2532-2540.
38. Rougier P, Van Cutsem E, Bajetta E, Niederle N, Possinger K, Labianca R, Navarro M, Morant R, Bleiberg H, Wils J, Awad L, Herait P, Jacques C: Randomized trial of irinotecan vs fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998, 35:1407-1412.
39. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
40. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000, 355:1041-1047.
41. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18:136-147.
42. Elias DM, Sideris L: Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin N Am 2003, 12:755-769.
43. Elias D, Raynard B, Farkhondeh F: Peritoneal carcinomatosis of colonrectal origin: long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. (submitted for publication)
44. Gomes da Silva RG, Sugarbaker PH: Analysis of 10 prognostic factors in 70 patients having complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J Am Coll Surg. (Submitted for publication)
45. Sugarbaker PH, Yu W, Yonemura Y: Gastrectomy, peritonectomy and perioperative intraperitoneal chemotherapy: evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol 2003, 21:233-248.
46. Yonemura Y, Ninomiya I, Kaji M, Sugiyama K, Fujimura K, Sawa T, Katayama K, Tanaka S, Hirono Y, Miwa K: Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg 199S, 19:450-455.
47. Yonemura Y, Bandou E, Sawa T: Neoadjuvant treatment of gastric cancer with peritoneal dissemination. (submitted for publication)
48. Yancik R: Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis and mortality. Cancer 1993, 71:517-523.
49. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996, 334:1-6.
50. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21:3194-200.
51. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen P, Lele S, Copeland LJ, Walker JL, Burger RA: Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:77-79.
52. Urano M, Kuroda M, Nishimura Y: For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 1999, 15:79-107.
53. Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH: Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial. World J Surg 2001, 25:985-990.
54. Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol 2004, 10(18):2727-2730.